AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

  • Order Reprints

  • Print Article

In a quarterly earnings report out Friday, the drugmaker AbbVie cut its full-year earnings guidance, and a number of its key drugs missed Wall Street estimates.

The company’s first-quarter earnings were roughly in line with Wall Street expectations.

AbbVie (ticker: ABBV) reported adjusted diluted earnings of $3.16 per share, slightly beating…

William Murphy

Related post